Aminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients

被引:6
|
作者
Grucz, Traci M. [1 ]
Kruer, Rachel M. [2 ]
Bernice, Fidelia [1 ]
Lipsett, Pamela A. [3 ,4 ]
Dorman, Todd [4 ]
Sugrue, David [1 ]
Jarrell, Andrew S. [1 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Pharm, 600 North Wolfe St,Carnegie 180, Baltimore, MD 21287 USA
[2] Indiana Univ Hlth, Dept Pharm, Indianapolis, IN USA
[3] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA
关键词
aminoglycosides; critical illness; pharmacokinetics; therapeutic drug monitoring; PEAK CONCENTRATION; GENTAMICIN; PHARMACOKINETICS; AMIKACIN;
D O I
10.1089/sur.2020.012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: At a tertiary referral and Level I trauma center, current institutional guidelines suggest initial aminoglycoside doses of gentamicin or tobramycin 4 mg/kg and amikacin 16 mg/kg for patients admitted to surgical intensive care units (SICUs) with suspected gram-negative infection. The objective of this study was to evaluate initial aminoglycoside dosing and peak serum drug concentrations in critically ill surgery patients to characterize the aminoglycoside volume of distribution (V-d) and determine an optimal standardized dosing strategy. Methods: This retrospective, observational, single-center study included adult SICU patients who received an aminoglycoside for additional gram-negative coverage. Descriptive statistics were used to evaluate the patient population, aminoglycoside dosing, and V-d. Multivariable linear regression was applied to determine variables associated with greater aminoglycoside V-d. The mortality rate was compared in patients who achieved adequate initial peak concentrations versus those who did not. Results: One hundred seventeen patients received an aminoglycoside in the SICUs, of whom 58 had an appropriately timed peak concentration measurement. The mean Acute Physiology, Age, and Chronic Health Evaluation (APACHE) II score was 27.8 +/- 8.9. The V-d in patients receiving gentamicin, tobramycin, and amikacin was 0.49 +/- 0.10, 0.41 +/- 0.09, and 0.53 +/- 0.13 L/kg, respectively. Together, the mean aminoglycoside V-d was 0.50 +/- 0.12 L/kg. Gentamicin or tobramycin 5 mg/kg achieved goal peak concentrations in 24 patients (63.2%), and amikacin 20 mg/kg achieved the desired concentrations in nine patients (50.0%). Net fluid status, Body Mass Index, and vasopressor use were not predictive of V-d. There was no difference in the in-hospital mortality rate in patients who achieved adequate peak concentrations versus those who did not (26.8% versus 26.7%; p = 0.99). Conclusion: High aminoglycoside doses are needed in critically ill surgery patients to achieve adequate initial peak concentrations because of the high V-d. Goal peak concentrations were optimized at doses of gentamicin or tobramycin 5 mg/kg, and amikacin 20 mg/kg.
引用
收藏
页码:859 / 864
页数:6
相关论文
共 50 条
  • [1] AMINOGLYCOSIDE DOSING AND VOLUME OF DISTRIBUTION IN CRITICALLY ILL SURGERY PATIENTS
    Grucz, Traci
    Kruer, Rachel
    Bernice, Fidelia
    Lipsett, Pamela
    Dorman, Todd
    Sugrue, David
    Jarrell, Andrew
    CRITICAL CARE MEDICINE, 2020, 48
  • [2] Suboptimal aminoglycoside dosing in critically ill patients
    Rea, RS
    Capitano, B
    Bigos, K
    Bies, R
    Smith, R
    CRITICAL CARE MEDICINE, 2005, 33 (12) : A171 - A171
  • [3] Suboptimal Aminoglycoside Dosing in Critically Ill Patients
    Rea, Rhonda S.
    Capitano, Blair
    Bies, Robert
    Bigos, Kristin L.
    Smith, Randall
    Lee, Howard
    THERAPEUTIC DRUG MONITORING, 2008, 30 (06) : 674 - 681
  • [4] Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients
    Mann, HJ
    Wittbrodt, ET
    Baghaie, AA
    Cerra, FB
    PHARMACOTHERAPY, 1998, 18 (02): : 371 - 378
  • [5] AMINOGLYCOSIDE VOLUME OF DISTRIBUTION AND ILLNESS SEVERITY IN CRITICALLY ILL SEPTIC PATIENTS
    MARIK, PE
    ANAESTHESIA AND INTENSIVE CARE, 1993, 21 (02) : 172 - 173
  • [6] Comment: once-daily aminoglycoside dosing in critically ill patients
    Wolfe, TA
    Dasta, JF
    ANNALS OF PHARMACOTHERAPY, 1998, 32 (10) : 1109 - 1110
  • [7] Once-daily aminoglycoside dosing for critically ill patients with renal insufficiency
    Smith, CJ
    Marini, CP
    Ritter, GS
    CRITICAL CARE MEDICINE, 1999, 27 (12) : A124 - A124
  • [8] INTRAPATIENT VARIATION OF AMINOGLYCOSIDE PHARMACOKINETICS IN CRITICALLY ILL SURGERY PATIENTS
    FUHS, DW
    MANN, HJ
    KUBAJAK, CA
    CERRA, FB
    CLINICAL PHARMACY, 1988, 7 (03): : 207 - 213
  • [9] GENTAMICIN VOLUME OF DISTRIBUTION IN CRITICALLY ILL SEPTIC PATIENTS
    TRIGINER, C
    IZQUIERDO, I
    FERNANDEZ, R
    RELLO, J
    TORRENT, J
    BENITO, S
    NET, A
    INTENSIVE CARE MEDICINE, 1990, 16 (05) : 303 - 306
  • [10] AMINOGLYCOSIDE NEPHROTOXICITY IN CRITICALLY ILL SURGICAL PATIENTS
    SCHENTAG, JJ
    PLAUT, ME
    CERRA, FB
    WELS, PB
    WALCZAK, P
    BUCKLEY, RJ
    JOURNAL OF SURGICAL RESEARCH, 1979, 26 (03) : 270 - 279